Search results for "Disease remission"

showing 2 items of 2 documents

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

2020

Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are giv…

glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusiness
researchProduct

OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

2020

Abstract Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life. Methods Patients from the prospectively maintained ENEIDA registry treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score (PMS). The short-term response was assessed at week 4, 8 and 16. The last-observation-carried-forward method was used in patients that stopped tofacitinib before the time-points for clinical assessment. Variables associated with short-term remission at week 8 were identified by logistic regression analysis. The cumulative retention rate and the cumulative incidence o…

medicine.medical_specialtyTofacitinibbusiness.industryHypertriglyceridemiaGastroenterologyGeneral MedicineReal world evidencemedicine.diseaseUlcerative colitisInternal medicineDisease remissionmedicinePredictor variableAdverse effectbusinessSurvival analysisJournal of Crohn's and Colitis
researchProduct